Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097205 | 0.91 | PTGS2 (0.52) | PTGS2PTGS1PDPK1CYP2C9EPHX2 | |
| SCHEMBL6097217 | 0.79 | PTGS1 (0.55) | PTGS2PTGS1PDPK1CYP2C9MAPT | |
| SCHEMBL6096333 | 0.79 | CA1 (0.48) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6099805 | 0.77 | CA1 (0.46) | CA12CA1CA2CA9 | |
| SCHEMBL6096538 | 0.76 | CA1 (0.48) | PTGS2EPHX2AKR1C3CA12CA1 | |
| SCHEMBL4246189 | 0.75 | PTGS2 (0.56) | PTGS2PTGS1CYP2C9EPHX2MAPT | |
| SCHEMBL6097735 | 0.74 | PTGS1 (0.70) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL6097074 | 0.74 | PTGS2 (0.61) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL6096982 | 0.73 | PTGS2 (0.61) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL6096735 | 0.73 | CA1 (0.52) | CA12CA1CA2CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001917-B2 | Pyrazole compounds as anti-inflammatory and analgesic agents | WARNER LAMBERT COMPANY LLC (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1495005-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | Pfizer Japan Inc. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | HIRANO MISATO (JP) | 2004-01-29 | — | — | US | disclosed |
| WO-2003087061-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | PTGER1, PTGS1, PTGIR | PTGS2 10/4885PTGS1 2/4885PDPK1 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.